Board resignations amid low cash and strategic review drive INDP selloff
- INDP dropped sharply on June 5 (~23% to $3.66 close) after 8-K revealed directors David E. Lazar and Avraham Ben-Tzvi resigned all roles effective June 5; COO Walt Linscott resigned June 1 to consultant (no disagreements cited).
- This follows May 15 Q1 2026 results: cash fell to $1.5M (from $8.5M YE2025), $7M operating burn, no financing raised, R&D wound down as company reassesses Decoy platform and priorities.
- Company explicitly seeking additional capital and evaluating financing/strategic options post-management transition, raising dilution and viability concerns in microcap biotech.
- Massive June 4 surge (>100% on 40M+ volume, low ~1.4M float) tied to financing/strategic uncertainty speculation; June 5-8 moves reflect post-squeeze reversal and selling pressure.
- Multiple board/executive changes throughout 2026 add to governance and direction uncertainty; no new clinical data or earnings on June 8.
- Continued ~15% decline on June 8 aligns with lingering fallout from these verifiable prior events per SEC filings and press releases.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.